Search clinical trials for: Trastuzumab/pertuzumab

Total 1376 results

UCB Pharma

Completed

Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

Japan
University of Chicago

Not yet recruiting

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Breast Cancer | HER2-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

United States
The University of Hong Kong-Shenzhen Hospital
Tianjin Happy Life Technology Co., Ltd.

Not yet recruiting

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

Feasibility | Safety | Targeted Molecular Therapy | Effectiveness
Baylor Breast Care Center

Recruiting

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer (RESPONSE)

Breast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer Invasive

United States
Tanvex BioPharma USA, Inc.

Completed

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

Breast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Early-stage Breast Cancer

Belarus, Chile, Georgia, Hungary, India, Mexico, Peru, Philippines, Russian Federation, Ukraine
Japan Breast Cancer Research Group
Eisai Co., Ltd.

Recruiting

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Breast Cancer

Japan
The Greater Poland Cancer Centre

Active, not recruiting

Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy (SPORTNATHy)

Breast Cancer

Poland
iOMEDICO AG
Amgen; Arbeitsgemeinschaft fur Internistische Onkologie

Withdrawn

A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer (ATTILA)

Advanced Breast Cancer | HER2-positive Breast Cancer

Germany
Jonsson Comprehensive Cancer Center
Novartis; Seagen Inc.

Recruiting

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditions

United States
Boehringer Ingelheim

Completed

Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours

Neoplasms

Japan
Hoffmann-La Roche
Latin American Cooperative Oncology Group

Active, not recruiting

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Breast Cancer

Colombia, Guatemala, Argentina, Brazil, Chile, Cuba, Mexico, Peru, Uruguay, Dominican Republic
AstraZeneca
Daiichi Sankyo Company, Limited

Active, not recruiting

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (DB-07)

Metastatic Breast Cancer

United States, Italy, India, Taiwan, Germany, Korea, Republic of, Brazil, Poland, Russian Federation, Turkey, Spain, Australia, France, Canada, United Kingdom
Spanish Breast Cancer Research Group

Completed

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer (ChangHER-SC)

Breast Cancer

Spain
University of Texas Southwestern Medical Center
Merck Sharp & Dohme LLC; Breast Cancer Research Foundation

Active, not recruiting

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab

Breast Cancer | HER2-positive Breast Cancer

United States
Dana-Farber Cancer Institute
Genentech, Inc.

Recruiting

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)

Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Breast Cancer | Invasive Carcinoma of the Breast | Node Negative Breast Cancer | Micrometastasis Breast Cancer

United States
Fudan University
Hoffmann-La Roche

Unknown

Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer (PCH)

Breast Cancer

China
Hoffmann-La Roche

Completed

A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (SAPPHIRE)

Breast Cancer

Australia
Shengjing Hospital

Recruiting

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

Stage II-III Breast Cancer

China
Nantes University Hospital

Unknown

Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+ (RIT 90YEpra)

Acute Lymphoblastic Leukemia

France
H. Lee Moffitt Cancer Center and Research Institute
ImmunoRestoration

Recruiting

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

HER2-positive Breast Cancer

United States
European Organisation for Research and Treatment...

Active, not recruiting

Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (INNOVATION)

Malignant Neoplasm of Stomach | Malignant Neoplasm of Cardio-esophageal Junction of Stomach | Epidermal Growth Factor Receptor (EGFR) Protein Overexpression

Spain, Korea, Republic of, Singapore, Switzerland, Germany, United Kingdom, Italy, France, Estonia, Belgium, Netherlands, Norway, Portugal
Nantes University Hospital
Chugai Pharmaceutical; French Innovative Leukemia Organisation

Completed

Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk (LAM2006IR)

Acute Myeloid Leukemia

France
Orano Med LLC

Completed

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Stomach Neoplasms | Breast Neoplasms | Pancreatic Neoplasms | Ovarian Neoplasms | Peritoneal Neoplasms

United States
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Male Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States, Puerto Rico
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage II Breast Cancer AJCC v8 | Prognostic Stage IIA Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer... and other conditions

United States, Puerto Rico
Samsung Bioepis Co., Ltd.

Terminated

A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC

Breast Neoplasms

Ukraine, Romania, Russian Federation, France, Bulgaria, Czechia, Poland
University Medical Center Groningen

Completed

89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition (AUY922)

Breast Cancer

Netherlands
Gustave Roussy, Cancer Campus, Grand Paris
Hoffmann-La Roche

Recruiting

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program)

Breast Cancer

France
Shanghai Jiao Tong University School of Medicine
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Breast Cancer Invasive

China
Charite University, Berlin, Germany
European Organisation for Research and Treatment of Cancer - EORTC; Centre... and other collaborators

Completed

International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010

Acute Lymphoblastic Leukemia (ALL)

United Kingdom, Norway, Germany, Italy, France, Belgium, Denmark, Australia, Austria, Czechia, Finland, Israel, Japan, Netherlands, Poland, Portugal, Switzerland
Dana-Farber Cancer Institute
MacroGenics; Translational Breast Cancer Research Consortium

Active, not recruiting

MARGetuximab Or Trastuzumab (MARGOT) (MARGOT)

Breast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage III Breast Cancer

United States
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer (PERUSE)

Breast Neoplasms

Italy, Netherlands, Belgium, United Kingdom, Argentina, Austria, Brazil, China, Ecuador, Estonia, Finland, France, Germany, Greece, Mexico, Peru, Poland, Portugal, Slovenia, Spain, United Arab Emirates, Canada, Hungary, Israel, Sweden, Tu... and more
Massachusetts General Hospital
Dana-Farber Cancer Institute; Takeda

Not yet recruiting

Vedolizumab for the Treatment of Collagenous Gastritis

Collagenous Gastritis

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer

Recurrent Salivary Gland Carcinoma | Stage III Major Salivary Gland Cancer AJCC v8 | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland Carcinoma

United States
Biogen

Completed

CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

Breast Cancer

United States
AstraZeneca
Daiichi Sankyo

Completed

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer (DESTINY-B12)

Breast Cancer

Denmark, Finland, Italy, Norway, Spain, Sweden, Poland, United States, Canada, Germany, Japan, Netherlands, Portugal, Switzerland, Australia, United Kingdom, Belgium, Ireland
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

Breast Cancer

China
Pfizer

Completed

A Study Evaluating The Safety Of PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-06)

Healthy

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

Sarcoma | Breast Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer (JACOB)

Gastric Cancer

Austria, Belgium, Brazil, Canada, China, Croatia, Finland, Hungary, Italy, Korea, Republic of, Mexico, Poland, Spain, Turkey, United States, Kazakhstan, Peru, Russian Federation, Switzerland, Taiwan, Thailand, Germany, Japan, Malaysia, ... and more
Byondis B.V.

Completed

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Endometrial Cancer

Korea, Republic of, Singapore, Russian Federation, Ukraine, United States, Poland, Serbia
Nanogen Pharmaceutical Biotechnology Joint Stock...
Vietstar Biomedical Research; MedProve Inc

Completed

Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients

Breast Cancer Recurrent | Breast Cancer Female | Breast Cancer Metastatic

Vietnam
Nanogen Pharmaceutical Biotechnology Joint Stock...
Vietstar Biomedical Research; MedProve Inc

Completed

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

Breast Cancer Recurrent | Breast Cancer Female | Breast Cancer Metastatic

Vietnam
Shen Lin

Unknown

Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

Colorectal Cancer | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancer | Targeted Therapy | HER2

China
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Withdrawn

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | HER2 Positive Breast Carcinoma | Metastatic Breast Carcinoma

United States
UCB Biopharma S.P.R.L.
Pharmaceutical Research Associates; Richmond Pharmacology Limited; Eurofins; ACM... and other collaborators

Completed

Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the Blood

Systemic Lupus Erythematosus

United Kingdom
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma

Sarcoma
Shanghai Henlius Biotech

Completed

A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male Subjects

Healthy

China
Yale University
Genentech, Inc.

Withdrawn

Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

Paget's Disease of the Vulva

United States

Search clinical trials for: Trastuzumab/pertuzumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations